No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19 - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of General Medicine Année : 2022

No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19

, (1, 2) , (3) , (4) , , (2, 4) , , (5) , (4) , (4) , (4, 2)
1
2
3
4
5

Résumé

Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58-1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients.

Dates et versions

hal-03767758 , version 1 (02-09-2022)

Identifiants

Citer

Adrien Chan Sui Ko, Alexandre Candellier, Marie Mercier, Cedric Joseph, Hortense Carette, et al.. No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19. International Journal of General Medicine, 2022, 15, pp.6645-6651. ⟨10.2147/IJGM.S367273⟩. ⟨hal-03767758⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More